The $800M Startup That Still Needs Half a Billion More

The drug is currently in a Phase 1/2 trial across multiple solid tumor types. But the real prize is desmoid tumors, a rare and painful condition where abnormal fibrous tissue grows aggressively. Desmoid tumors are essentially driven by the exact pathway zolucatetide is built to shut down; it's like designing a key specifically for this lock.

About $150 million of the IPO proceeds will fund a Phase 3 registrational trial in desmoid tumors. Another roughly $120 million goes toward expanding zolucatetide into additional cancers, including colorectal cancer, liver cancer, and a hereditary condition called familial adenomatous polyposis. The remaining $130 million is earmarked for earlier-stage programs targeting prostate cancer, still in preclinical development.

The company also just inked a deal with Regeneron Pharmaceuticals, which is buying $75 million of stock in a private placement alongside the IPO at a 10% discount. That deal is part of a broader collaboration worth up to $2.3 billion if all milestones are hit, focused on a new class of drugs combining antibodies with Parabilis' Helicon peptides.

The Underwriting Lineup Says a Lot

The banks running this deal aren't messing around. Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital are all on the ticket. That's the biotech equivalent of assembling the Avengers for your book report presentation. It signals serious institutional demand and suggests the roadshow is going well.

At the $18 midpoint, Parabilis would carry a post-IPO market cap of roughly $2 billion, with about 114 million shares outstanding if the overallotment is fully exercised. The company says the combined IPO and Regeneron proceeds should fund operations into the second half of 2029.

Why This IPO Is About More Than One Company

Biotech IPOs basically flatlined from 2022 through most of 2025. Rising interest rates and a brutal selloff scared investors away.

But 2026 has been a different story. In Q1 alone, biopharma companies raised $1.7 billion through IPOs, the strongest quarter since 2021. The median deal size more than doubled compared to the prior year. Kailera Therapeutics broke records with a roughly $625 million obesity-focused IPO in April. Eikon Therapeutics raised $381 million in February. Aktis Oncology kicked off the year with a $318 million debut.

The pattern is clear: bigger checks, fewer companies. Investors are writing large checks, but only for biotechs with real clinical data and a clear path forward. Think of it as a velvet rope policy; the club is open, but the bouncer got very selective.

Parabilis fits the profile. It has Phase 1/2 data across multiple tumor types, a registrational trial ready to launch, a blue-chip investor syndicate, and a Regeneron partnership that adds both cash and credibility. If this IPO prices well and trades strong, it sends a signal to every biotech sitting in the private market green room: your turn might be coming.

If it stumbles? The velvet rope gets tighter.

The Bottom Line

Parabilis is betting that a decade of work on "undruggable" targets, $800 million in private capital, and a drug that speaks directly to a rare tumor's biology will be enough to convince public market investors to write one of the biggest biotech checks of the year.

The science is compelling. The syndicate is strong. The timing, with the IPO window finally creaking open after years of drought, could hardly be better.

But compelling science and good timing don't guarantee anything. Post-IPO trading for the 2026 class has been mixed, and investors remain price-sensitive. Parabilis will need more than a great story; it'll need the data to keep delivering.

We'll know a lot more by Wednesday.

The Insulin That Kids Don't Have to Stab Themselves With

Inhaled insulin flopped spectacularly with adults. Now MannKind's Afrezza just became the first needle-free mealtime insulin approved for kids, targeting a population where needle fear isn't just annoying — it's clinically dangerous.